|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Rössler, Daniel 
ORCID: https://orcid.org/0000-0002-5652-5987; Öcal, Osman; Philipp, Alexander B.; Markwardt, Daniel; Munker, Stefan; Mayerle, Julia; Jochheim, Leonie S.; Hammer, Katharina; Lange, Christian M.; Geier, Andreas; Seidensticker, Max; Reiter, Florian P.; De Toni, Enrico N. und Ben Khaled, Najib
(2022):
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3065-3073
[PDF, 746kB]
ORCID: https://orcid.org/0000-0002-5652-5987; Öcal, Osman; Philipp, Alexander B.; Markwardt, Daniel; Munker, Stefan; Mayerle, Julia; Jochheim, Leonie S.; Hammer, Katharina; Lange, Christian M.; Geier, Andreas; Seidensticker, Max; Reiter, Florian P.; De Toni, Enrico N. und Ben Khaled, Najib
(2022):
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3065-3073
[PDF, 746kB]
Ben Khaled, Najib; Hammer, Katharina; Ye, Liangtao; Alnatsha, Ahmed; Widholz, Sebastian A.; Piseddu, Ignazio; Sirtl, Simon; Schneider, Julia; Munker, Stefan; Mahajan, Ujjwal Mukund; Montero, Juan Jose; Griger, Joscha; Mayerle, Julia; Reiter, Florian P. und De Toni, Enrico N.
(2022):
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
In: Cancers, Bd. 14, Nr. 21
[PDF, 2MB]